Medical devices, healthcare technology and the business of care
PMA approval · P070026

CERAMAX CERAMIC HIP SYSTEM

Depuy Orthopaedics, Inc. · Decision date Dec 23, 2010

MEDTECHLEDGER EXPLANATIONP070026

What did the FDA approve?

The FDA approved the CERAMAX Ceramic Total Hip System on December 23, 2010. The approval covers noncemented use in skeletally mature individuals undergoing primary total hip replacement for rehabilitation of hips damaged by noninflammatory degenerative joint disease or its composite diagnoses of osteoarthritis, avascular necrosis, and post-traumatic arthritis.

The record identifies this as an original PMA approval, not a supplement or manufacturing notice. The device is classified as a semi-constrained metal/ceramic/ceramic/metal hip prosthesis, cemented or uncemented, under product code MRA. The statement reports the approved indication but does not provide independent evidence of safety or clinical effectiveness.

FDA approval order statement

APPROVAL FOR THE CERAMAX CERAMIC TOTAL HIP SYSTEM. THIS DEVICE IS INDICATED FOR NONCEMENTED USE IN SKELETALLY MATURE INDIVIDUALS UNDERGOING PRIMARY TOTAL HIP REPLACEMENT SURGERY FOR REHABILITATION OF HIPS DAMAGED AS A RESULT OF NONINFLAMMATORY DEGENERATIVE JOINT DISEASE (NIDJD) OR ANY OF ITS COMPOSITE DIAGNOSES OF OSTEOARTHRITIS, AVASCULAR NECROSIS, AND POST-TRAUMATIC ARTHRITIS.
Regulatory pathway
Original PMA
Clinical specialty
Orthopedic
Decision date
Dec 23, 2010

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P070026
Regulatory pathway
Premarket approval application
Product code
MRA
Decision code
APPR
Decision date
Dec 23, 2010
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Prosthesis, hip, semi-constrained, metal/ceramic/ceramic/metal, cemented or uncemented.

Product code
MRA
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P070026 received

    Application receipt date recorded by FDA.

  2. P070026 · FDA decision

    APPR

  3. P070026/S129 · Related supplement

    CERAMAX CERAMIC HIP SYSTEM

Timeline entries are records held by MedtechLedger for P070026. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P070026

Product / regulatory recordCompanyPathwayDecision dateSource
Depuy Orthopaedics, Inc.PMA supplementSep 4, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Depuy Orthopaedics, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
700 Orthopaedic Dr., Warsaw, IN, 46582

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records